Microangiopathic hemolytic anemia pathophysiology

	Microangiopathic hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Microangiopathic hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Microangiopathic hemolytic anemia pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Microangiopathic hemolytic anemia pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Microangiopathic hemolytic anemia pathophysiology
on Microangiopathic hemolytic anemia pathophysiology
Microangiopathic hemolytic anemia pathophysiology in the news
Blogs on Microangiopathic hemolytic anemia pathophysiology
Directions to Hospitals Treating Microangiopathic hemolytic anemia
Risk calculators and risk factors for Microangiopathic hemolytic anemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In all causes, the mechanism of MAHA is the formation of a fibrin mesh due to increased activity of the system of coagulation.

The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.